Premier Biomedical, Inc. announced the filing of a patent application, Method For Slowing The Aging Process, by Mitchel S. Felder, MD, the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. Through its exclusive patent license agreement, Premier Biomedical will have exclusive rights to practice the invention. The patent application involves the removal of certain antigens associated with the aging process through an extracorporeal (outside the body) treatment of a patient's blood. By targeting these antigens with a complexing agent, causing them to bind together, they can be easily removed before returning the blood to the patient. This process can target several known aging antigens, such as mTOR (mammalian target of rapamycin), interleukin-6, TGF-beta, oxygen free radicals, Progerin, lipofuscin, etc.